AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.

Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.

Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.

Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.

ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.

Abbott Laboratories earnings put recent stock moves in context Abbott Laboratories (ABT) is back in focus after its latest quarterly earnings, where higher year over year sales came alongside lower net income and earnings per share, sharpening attention on upcoming estimates. See our latest analysis for Abbott Laboratories. After these earnings, Abbott Laboratories' recent rally stands out, with a 7 day share price return of 12.66% and a 30 day share price return of 14.51% contrasting with a...

The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.

JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?

BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Abbott's diversified healthcare business is one of the main reasons why it remains a reliable dividend stock.

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Prosecutors have declined to charge businesses in a number of recent cases—despite believing that senior employees were involved in wrongdoing.

The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.

Abbott Laboratories (ABT) beat Q2 expectations, with growth acceleration in the second half of 2026

Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.

This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.

The cyberattack follows Abbott’s recent $21 billion purchase of Exact Sciences. Abbott did not disclose what kind of information was accessed.

Wall Street closed lower on Thursday, dragged down by technology stocks, as investors assessed second-quarter earnings and a batch of economic data.

The Morning Bull - US Market Morning Update Friday, Jul, 17 2026 US stock futures are drifting slightly lower this morning, with key index contracts such as the E-mini S&P 500 and Nasdaq-100 off by around 0.1% to 0.4%, as investors weigh tighter financial conditions against mixed global growth signals. A planned 25% US tariff on some Brazilian imports raises questions about costs for companies tied to global trade and agriculture, while US crude stockpiles and the Strategic Petroleum Reserve...

A recent acquisition is already bearing fruit.

Memory stocks and semiconductor leaders fell as investor concerns over AI spending resurfaced and U.S.-Iran tensions re-escalated, today, July 16, 2026.

Abbott Laboratories (ABT) reports robust sales growth and raises full-year EPS guidance, driven by strong performance in Nutrition, Medical Devices, and Emerging Markets.

(Updates with closing levels throughout the story.) Wall Street's stock indexes fell Thursday aft

US equity indexes closed lower on Thursday amid a sell-off in technology stocks, and Iran threatened

Abbott Laboratories has reported its second-quarter 2026 results, with sales rising to US$12.59 billion from US$11.14 billion a year earlier, while net income fell to US$928 million and diluted EPS from continuing operations declined to US$0.53. Despite lower net income, Abbott delivered better-than-expected adjusted earnings, lifted its full-year 2026 adjusted EPS guidance, and highlighted strong growth in higher-margin Medical Devices and Cancer Diagnostics, signalling a continued shift in...

US benchmark equity indexes were lower intraday amid a sell-off in certain chip-related stocks as in

Abbott Laboratories (NYSE:ABT) shares rose nearly 11% on Thursday after the healthcare company reported second quarter 2026 results that topped Wall Street expectations and raised its full-year adjusted earnings guidance. The company posted adjusted diluted earnings per share of $1.31 for the...

Stock Market Today: The Nasdaq composite dropped Thursday as Sandisk and SK Hynix plunged. TSMC sold off on earnings.

ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.

The S&P 500 and Nasdaq Composite were down in late-morning trading Thursday, while the Dow Jones Ind

Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara

Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm r

AMD, Dell, Intel, and Micron shares fall as Wall Street questions how long the AI spending boom can last.

Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.

Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street's estimate of $1.28

Abbott Laboratories stock has fallen sharply over the past year, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and traditional market multiples currently point to the shares trading at a discount. The share price is down about 30.7% over the past year, which has pushed investor sentiment lower while opening a potential valuation gap. Progress in colorectal cancer diagnostics and partnerships in continuous glucose monitoring can support long term cash...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to $12.59 billion. Its non-GAAP profit of $1.31 per share was 2.6% above analysts’ consensus estimates.

Abbott stock jumped early Thursday on better-than-expected second-quarter metrics. The company also raised its 2026 profit view.

Abbott Laboratories (NYSE:ABT) delivered stronger-than-expected second-quarter results and increased its full-year earnings guidance, sending its shares about 2. 5% higher in premarket trading.

Abbott (ABT) delivered earnings and revenue surprises of +2.34% and +0.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- Abbott (NYSE:ABT) shares are trading higher premarket on Thursday after the company reported second-quarter earnings, topping consensus expectations and raising its full-year earnings guidance.

The healthcare company said its profit fell to $928 million, or 53 cents a share, in the second quarter, from $1.78 billion, or $1.01 a share, a year earlier.

Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.

US equity markets were mostly tracking in the red before the opening bell Thursday as traders await

Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.

Today Earnings (a.m): UnitedHealth, GE Aerospace, U.S. Bancorp, Citizens Financial, Abbott Laboratories, State Street, Taiwan Semiconductor Manufacturing Earnings (p.m.): Netflix, Intuitive Surgical Economic data: Weekly jobless claims, Philadelphia Fed business-outlook survey, retail sales, pending home sales index, business inventories Fed speakers: Fed Vice Chair Philip Jefferson is expected to speak, as is Dallas Fed President Lorie Logan.

Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.